Brief: Elicera Gets First Patent Allowance For ELC-201
01/09/2026 13:10
BRIEF-Elicera Gets First Patent Allowance For ELC-201 Sept 1 (Reuters) - Elicera Therapeutics AB ELIC.ST:
ELICERA THERAPEUTICS RECEIVES ITS FIRST NOTICE OF PATENT ALLOWANCE FOR ELC-201 - A JAPANESE PATENT PROTECTING THE ONCOLYTIC VIRUS CANDIDATE AGAINST SOLID TUMORS
PATENT GRANTS ELICERA EXCLUSIVE RIGHTS IN JAPAN FOR ELC-201 CANCER TREATMENT
Source text: ID:nWkrvbLbS
Further company coverage: ELIC.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Elicera Therapeutics AB
See all newsBrief: Elicera Therapeutics Completes Phase I Part Of Carma Study
Brief: Elicera Therapeutics Gets Medical Products Agency Approval To Advance CARMA Study
Brief: Elicera Gets Clearance To Use Highest ELC-301 Dose Ahead Of Phase IIa
Brief: Elicera Gets First Patent Allowance For ELC-201
Brief: Elicera Receives Notice Of Allowance For U.S. Patent Application